Clinical trials: Mucormycosis
Maxillofacial Trauma, Face Cancer
Evaluation of Using 3D Printed PEEK Facial Implants in Repairing Maxillofacial Deformities
Objective: Evaluation of using 3D printed polyether ether ketone facial implants in repairing maxillofacial deformities. Research materials and methods: The research sample consisted of 10 patients with facial deformities…
- Conditions
- Maxillofacial Trauma, Face Cancer, Mucormycosis
- Trial name
- NCT05348434
- Testing
- 3D printed polyether ether ketone facial implants in repairing maxillofacial deformities
- Where
- Syria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Latakia University
Mucormycosis
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
- Trial name
- NCT00419770
- Testing
- deferasirox, Liposomal amphotericin B
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Fungal Infection, Aspergillosis
Isavuconazole in Critically Ill Patients: Efficacy and Safety
Due to factors such as disease status, gastrointestinal conditions, commonly used medications (e.g., vasopressors), and cardiac output, the plasma concentration of isavuconazole in critically ill patients may differ from that in…
- Conditions
- Fungal Infection, Aspergillosis, Mucormycosis
- Trial name
- NCT07080359
- Testing
- Isavuconazole treatment
- Volunteers
- 75 people
- Sponsor
- Shanghai 10th People's Hospital
Mucormycosis
Mucormycosis in ICU
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns.
- Trial name
- ZygoRéa (NCT03387696)
- Where
- 21 sites in France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Grenoble
Invasive Mucormycosis, Invasive Aspergillosis
A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.
- Trial name
- NCT03816176
- Testing
- Isavuconazonium sulfate
- Where
- 10 sites in United States, Belgium and 1 more
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Mucormycosis; Rhinocerebral (Etiology), COVID-19
World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt
Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosis infection associated with Covid 19 viral infection
- Trial name
- NCT06267326
- Testing
- debridment
- Where
- Egypt
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nasser Institute For Research and Treatment
Mucormycosis
Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis
This Study evaluates the performance (sensitivity, specificity, positive and negative predictive value values and likelihood ratios) of the DNA detection test for the diagnosis of mucormycosis by comparing it to the routine tests…
- Trial name
- MODIMUCOR (NCT02845934)
- Testing
- blood sample
- Where
- 10 sites in France
- Volunteers
- 248 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Pulmonary Mucormycosis
Chest CT Scan in Pulmonary Mucormycosis: Prognostic Value
Invasive pulmonary fungal infections caused by Mucorales are rare but severe and rapidly progressive, affecting immunocompromised patients.
- Trial name
- RadioMucor (NCT07339800)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Strasbourg, France
Mucormycosis; Pulmonary (Etiology)
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management of mucormycosis.
- Trial name
- NCT05468372
- Testing
- Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B
- Where
- India
- Volunteers
- 82 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Rhinocerebral Mucormycosis
Endoscopic Surgical Treatment of Rhino-Sinusal Mucormycosis
Radical endoscopic transnasal surgery associated with medical treatment with liposomal amphotericine B may increase the local control of Rhino-Sinusal Mucormycosis and the survival rate.
- Trial name
- MICCA (NCT02226705)
- Testing
- Multiple transnasal endoscopic surgeries
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mucormycosis in Hematologic Malignancies
Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
This clinical trial, a single-arm prospective study, aims to evaluate the efficacy and safety of liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole in treating adult patients with malignant…
- Trial name
- NCT07185503
- Testing
- liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pulmonary Mucormycosis
Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis
To assess the safety and feasibility of combined inhalational and intravenous amphotericin B therapy for the treatment of pulmonary mucormycosis.
- Trial name
- NCT04502381
- Testing
- Inhaled amp B deoxycholate+intravenous liposomal amp B, Intravenous liposomal amphotericin B alone
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Aspergillos, Mucormye
Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections
Background: Fungal infections can cause serious disease in the lungs and other parts of the body. About 3.8 million people die with fungal infections each year.
- Conditions
- Aspergillos, Mucormye, Dimorphic, Other Molds
- Trial name
- NCT07704333
- Testing
- [18F]-Fluorocellobiose ([18F]FCB)
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Covid19, Mucormycosis
Mucormycosis in COVID-19
The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge.
- Conditions
- Covid19, Mucormycosis, Aspergillosis, Candida Infection
- Trial name
- MUNCO (NCT04935463)
- Where
- United States
- Volunteers
- 728 people
- Sponsor
- Montefiore Medical Center
Mucormycosis
COVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
We aimed to describe the frequency; presentations, predictors, in-hospital outcome of mucormycosis patients in the scope of COVID-19.
- Trial name
- NCT05074043
- Testing
- antiviral, surgical
- Where
- Egypt
- Volunteers
- 433 people
- Sponsor
- Assiut University
Mucormycosis
COVID-19 and Rhino-orbital Mucormycosis
Detect the clinical presentation and outcome of post covid-19 fungal mucormycosis in patients referred to Minia university Hospital.
- Trial name
- NCT05212961
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Minia University
Mycoses
Descriptive Epidemiology on Management of Mucormycosis
This is an observational chart review of all patients with confirmed and probable diagnosis of mucormycosis at 19 centers across Indian hospital. Data will collect using a standardized CRF.
- Trial name
- NCT03429023
- Where
- 13 sites in India
- Volunteers
- 500 people
- Sponsor
- Fungal Infection Study Forum
Mucormycosis
Mucorales PCR Screening in At-risk Hematology Patients
Patients with leukemia are treated with intensive chemotherapy and often have to undergo a stem cell transplantation which makes their immune system extremely vulnerable.
- Trial name
- MUCOPS (NCT05925660)
- Testing
- Mucorales PCR (MucorGenius, PathoNostics, Maastricht, The Netherlands)
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven